EMA Authorised: Calquence (acalabrutinib;acalabrutinib maleate) — AstraZeneca AB

View source ↗

Summary

AstraZeneca's Calquence (acalabrutinib, acalabrutinib maleate) has been authorised by EMA for chronic lymphocytic leukemia and related B-cell leukemias.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Leukemia Lymphocytic Chronic B-cell

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• acalabrutinib maleate (acalabrutinib)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Lymphocytic, Chronic, B-Cell. MAH: AstraZeneca AB. Decision date: 26/05/2026